Induction and postremission therapy: new agents (Q73149868)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12646937 AND SRC:MED&resulttype=core&format=json

1 November 2019

title

Induction and postremission therapy: new agents (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12646937 AND SRC:MED&resulttype=core&format=json

1 November 2019

author name string

R M Stone

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12646937 AND SRC:MED&resulttype=core&format=json

1 November 2019

publication date

1 March 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12646937 AND SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12646937 AND SRC:MED&resulttype=core&format=json

1 November 2019

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12646937 AND SRC:MED&resulttype=core&format=json

1 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12646937 AND SRC:MED&resulttype=core&format=json

1 November 2019

page(s)

496-498

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12646937 AND SRC:MED&resulttype=core&format=json

FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model

1 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402864

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402864

7 January 2021

Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402864

7 January 2021

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402864

7 January 2021

Role of the microenvironment in promoting angiogenesis in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402864

7 January 2021

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402864

7 January 2021

Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402864

7 January 2021

Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402864

7 January 2021

Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402864

7 January 2021

Role of FLT3 in leukemia

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402864

7 January 2021

Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3.

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402864

7 January 2021

Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402864

7 January 2021

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402864

7 January 2021

Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402864

7 January 2021

Histone deacetylase inhibitors as new cancer drugs

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402864

7 January 2021

Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2.

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402864

7 January 2021

Emergence of multidrug resistance in leukemia cells during chemotherapy: mechanisms and prevention

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402864

7 January 2021

Differential effects of the MDR1 (multidrug resistance) gene-activating agents on protein kinase C: evidence for redundancy of mechanisms of acquired MDR in leukemia cells.

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402864

7 January 2021

The (patho)physiological functions of the MRP family

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402864

7 January 2021

Noninvasive detection of multidrug resistance in patients with hematological malignancies: are we there yet?

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402864

7 January 2021

Thalidomide for the treatment of patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402864

7 January 2021

Efficacy and safety of thalidomide in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402864

7 January 2021

Tyrosine kinase inhibitors: from rational design to clinical trials

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2402864

7 January 2021